Johnson & Johnson Highlights Positive Results from MEMBRANE Trial Published in JAMA Neurology

Study demonstrated middle meningeal artery embolization with TRUFILL n-BCA was associated with reduced chronic subdural hematoma recurrence or progression versus standard of care alone

Findings support the growing role of MMA embolization in chronic subdural hematoma care

Irvine, CA – June 19, 2026 – Today, Johnson & Johnson announced publication of the primary results from the MEMBRANE randomized controlled trial in JAMA Neurology. The study showed that adding middle meningeal artery embolization (MMAe) with TRUFILL n-BCA to standard of care (SOC), was associated with reduced cSDH recurrence and re-intervention versus standard of care alone.

MEMBRANE is a prospective, multicenter, open-label randomized controlled trial that randomized 376 patients across 30 sites in the United States and China, evaluating MMA embolization across both surgical and non-surgical chronic subdural hematoma treatment pathways.

Participants treated with SOC plus MMAE with TRUFILL n-BCA were significantly less likely to meet the prespecified composite primary end point of residual or re-accumulation of cSDH >10mm or the need for surgical re-intervention within 6 months than those treated with SOC alone. This corresponds to a 47% reduction in odds.

“These results reinforce the growing clinical evidence supporting middle meningeal artery embolization as an important treatment strategy for chronic subdural hematoma,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “The MEMBRANE study adds meaningful randomized evidence demonstrating that embolization with TRUFILL n-BCA can help reduce recurrence and re-intervention while supporting positive patient outcomes.”

Additional findings from the MEMBRANE study included:

• The embolization group had a numerically lower all cause mortality at six months (3.3% vs 8.4%).
• At 3 months, 85.3% vs 77.0% achieved good functional outcomes; MMAE met the trial’s non-inferiority threshold
• High procedural success, with successful embolization achieved in 98.9% of cases

“Chronic subdural hematoma remains a challenging condition with meaningful risk of recurrence, particularly in elderly and medically complex patients,” said Chris Kellner, MD, Cerebrovascular Center, Mount Sinai Health System, and MEMBRANE Study Co-Principal Investigator. “The MEMBRANE data provide important evidence that middle meningeal artery embolization with TRUFILL n-BCA can reduce recurrence and the need for additional intervention while demonstrating an encouraging safety profile.”

Chronic subdural hematoma is a common neurological condition, particularly in aging populations, and is associated with substantial morbidity, mortality, and healthcare utilization. Publication of the MEMBRANE results in JAMA Neurology adds to the growing body of randomized clinical evidence supporting middle meningeal artery embolization as part of comprehensive chronic subdural hematoma management.

Cardiovascular Solutions from Johnson & Johnson MedTech

Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit J&J MedTech neurointerventional.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopedics, vision, and cardiovascular solutions at jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. 

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to TRUFILL n-BCA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

© Johnson & Johnson and its affiliates 2026. All rights reserved.

Media contact:

James Alley

Jalley1@its.jnj.com